Drugs that contain Patisiran Sodium
1. List of Onpattro drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8334373 | ALNYLAM PHARMS INC | Nuclease resistant double-stranded ribonucleic acid |
May, 2025
(2 years from now) | |
| US10240152 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of transthyretin |
Oct, 2029
(6 years from now) | |
| US8168775 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of transthyretin |
Oct, 2029
(6 years from now) | |
| US11079379 | ALNYLAM PHARMS INC | Methods of treating transthyretin (TTR) mediated amyloidosis |
Aug, 2035
(12 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9943539 | ALNYLAM PHARMS INC | 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations |
Nov, 2023
(9 months from now) | |
| US9943538 | ALNYLAM PHARMS INC | 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations |
Nov, 2023
(9 months from now) | |
| US8642076 | ALNYLAM PHARMS INC | Lipid containing formulations |
Oct, 2027
(4 years from now) | |
| US8822668 | ALNYLAM PHARMS INC | Lipid formulations for nucleic acid delivery |
Apr, 2029
(6 years from now) | |
| US9364435 | ALNYLAM PHARMS INC | Lipid formulations for nucleic acid delivery |
Apr, 2029
(6 years from now) | |
| US8058069 | ALNYLAM PHARMS INC | Lipid formulations for nucleic acid delivery |
Apr, 2029
(6 years from now) | |
| US8492359 | ALNYLAM PHARMS INC | Lipid formulations for nucleic acid delivery |
Apr, 2029
(6 years from now) | |
| US11141378 | ALNYLAM PHARMS INC | Lipid formulations for nucleic acid delivery |
Apr, 2029
(6 years from now) | |
| US9234196 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of transthyretin |
Oct, 2029
(6 years from now) | |
| US8741866 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of transthyretin |
Oct, 2029
(6 years from now) | |
| US8802644 | ALNYLAM PHARMS INC | Lipid formulation |
Oct, 2030
(7 years from now) | |
| US8158601 | ALNYLAM PHARMS INC | Lipid formulation |
Nov, 2030
(7 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Aug 10, 2025 |
| New Chemical Entity Exclusivity (NCE) | Aug 10, 2023 |
NCE-1 date: August, 2022
Market Authorisation Date: 10 August, 2018
Treatment: Treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis
Dosage: SOLUTION;INTRAVENOUS
More Information on Dosage
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic